Literature DB >> 15582125

Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice.

Isabelle A Leclercq1, Geoffrey C Farrell, Christine Sempoux, Aileen dela Peña, Yves Horsmans.   

Abstract

BACKGROUND/AIMS: While oxidative stress is a feature of non-alcoholic steatohepatitis, the causal link between oxidative stress and inflammatory recruitment has yet to be demonstrated. We analysed the role of NF-kappaB redox-sensitive signalling pathway of inflammatory recruitment in experimental steatohepatitis.
METHODS: Mice were fed the methionine and choline deficient (MCD) or the control diet, with or without curcumin, an NF-kappaB inhibitor, for up to 4 weeks. Histopathology, lipoperoxides, NF-kappaB/DNA binding and expression of NF-kappaB-regulated genes were assessed.
RESULTS: MCD-fed mice developed steatohepatitis accompanied by dramatic accumulation of hepatic lipoperoxides, activation of NF-kappaB and induction of pro-inflammatory ICAM-1, COX-2, MCP-1 and CINC mRNA. Curcumin significantly reduced MCD-induced inflammation but had no effect on steatosis or on the level of hepatic lipid peroxides. Curcumin prevented the MCD-induced activation of NF-kappaB and decreased downstream induction of ICAM-1, COX-2 and MCP-1. However, it failed to reduce activation of AP-1, MAPK pathways or CINC expression.
CONCLUSIONS: Curcumin alleviates the severity of hepatic inflammation in experimental steatohepatitis induced by the MCD diet, an effect likely to be mediated via inhibition of NF-kB activation and dependent pro-inflammatory genes. The NF-kappaB pathway is one among several possible signalling pathways by which inflammation is recruited in experimental steatohepatitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15582125     DOI: 10.1016/j.jhep.2004.08.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  41 in total

Review 1.  Signal transductions and nonalcoholic fatty liver: a mini-review.

Authors:  Lu Zeng; Wai J Tang; Jin J Yin; Bei J Zhou
Journal:  Int J Clin Exp Med       Date:  2014-07-15

Review 2.  Herbal medicines and nonalcoholic fatty liver disease.

Authors:  Hong Yao; Yu-Jie Qiao; Ya-Li Zhao; Xu-Feng Tao; Li-Na Xu; Lian-Hong Yin; Yan Qi; Jin-Yong Peng
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 3.  Microbiota and nonalcoholic steatohepatitis.

Authors:  Kento Imajo; Masato Yoneda; Yuji Ogawa; Koichiro Wada; Atsushi Nakajima
Journal:  Semin Immunopathol       Date:  2013-12-14       Impact factor: 9.623

Review 4.  Animal models of nonalcoholic fatty liver disease.

Authors:  Lionel Hebbard; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-30       Impact factor: 46.802

Review 5.  Advances in antifibrotic therapy.

Authors:  Zahra Ghiassi-Nejad; Scott L Friedman
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-12       Impact factor: 3.869

Review 6.  Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.

Authors:  Lorne J Hofseth
Journal:  Cancer Lett       Date:  2008-04-25       Impact factor: 8.679

7.  Curcumin reduces the toxic effects of iron loading in rat liver epithelial cells.

Authors:  Donald J Messner; Gowsala Sivam; Kris V Kowdley
Journal:  Liver Int       Date:  2008-05-19       Impact factor: 5.828

8.  Pathophysiology of NASH: perspectives for a targeted treatment.

Authors:  Fabio Marra; Sophie Lotersztajn
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  Iron overload causes oxidative stress and impaired insulin signaling in AML-12 hepatocytes.

Authors:  Donald J Messner; Byung Han Rhieu; Kris V Kowdley
Journal:  Dig Dis Sci       Date:  2013-04-05       Impact factor: 3.199

10.  Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet.

Authors:  Mary E Rinella; Marc S Elias; Robin R Smolak; Tao Fu; Jayme Borensztajn; Richard M Green
Journal:  J Lipid Res       Date:  2008-01-28       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.